CJC 1295/IPAMORELIN blend 5mg/5mg

The CJC-1295/Ipamorelin Blend (5mg/5mg) is a premium-grade, research-only pepetide combination designed to stimulate the body;s natural growth hormone (GH) production. This synergistic blend combines CJC-1295 (without DAC) and Ipamorelin, two potent growth hormone secretagogoues, in a 1:1 ratio, with each vial containing 5mg of CJC-1295 and 5mg of Ipamorelin, totaling 10mg of active peptides. Synthesized and lyophilized in the USA, this product is crafted with >99% purity for use in laboratory research and experimentation. It is not intended for human consumption.

• CJC-1295 (No DAC): A synthetic peptide analog of growth hormone-releasing hormone (GHRH), consisting of 29 amino acids with four tetrasubstituted modifications to enhance stability and activity. CJC-1295 binds to GHRH receptors on the pituitary gland, promoting sustained pulsatile GH release with an estimated half-life of 6–8 days.
• Ipamorelin: A selective pentapeptide (five amino acids: alanine-aminosine-tryptophan-lysine-phenylalanine) classified as a growth hormone secretagogue (GHS). Ipamorelin mimics ghrelin, binding to the GHS-R1a receptor to trigger rapid GH release with a shorter half-life of approximately 2 hours. Its selectivity minimizes effects on other hormones like cortisol or prolactin.

The CJC-1295/Ipamorelin blend works synergistically to enhance GH secretion through complementary pathways:

• CJC-1295 stimulates the pituitary gland by binding to GHRH receptors, increasing the amplitude and frequency of GH pulses. This results in prolonged elevations of GH and Insulin-like growth factor 1 (IGF-1), which may support protein synthesis, cellular repair, and metabolic function.
• Ipamorelin acts as a ghrelin mimetic, rapidly stimulating GH release by targeting GHR-1a receptors. It promotes transient GH spikes, potentially aiding fat metabolism, muscle repair, and gastric motility without significantly affecting other pituitary hormones.
  When combined, Ipamorelin’s fast-acting GH stimulation complements CJC-1295’s longer-lasting effects, potentially leading to a 3–5 fold increase in GH levels compared to Ipamorelin alone, with sustained effects over days.

Research studies suggest the CJC-1295/Ipamorelin blend may be investigated for the following effects:

• Muscle Growth and Repair: Enhanced GH and IGF-1 levels may promote protein synthesis and muscle tissue regeneration, potentially benefiting studies on muscle development and recovery.
• Fat Metabolism: The blend may accelerate lipolysis (fat breakdown) by increasing GH, supporting research into body composition and energy utilization.
• Bone Health: Ipamorelin has been studies for its potential to improve bone mineral density, making it relevant for skeletal health research.
• Gastric Function: Ipamorelin may enhance bowel motility and gastric function, offering potential in neuroendocrine studies.
• Anti-Aging and Vitality: The combination may be explored for its role in mitigating age-related GH decline, with stidies showing GH increases of 200-1000% in subjects aged 21-61

• Total Peptide Content: 10mg per vial (5mg CJC-1295 + 5mg Ipamorelin)
• Form: Lyophilized powder (requires reconstitution with bacteriostatic water for research use)
• Purity: >99% (verified by third-party lab testing)
• Storage: Store at 2–8°C in a dry, dark place. Reconstituted peptides should be used within a limited timeframe to maintain stability.
• SKU: P-CJCIPAM-10
• CAS Numbers: CJC-1295 (863288-34-0), Ipamorelin (170851-70-4)
• Administration: Typically administered via subcutaneous injection in research settings.

While no officially approved dosage exists due to the research-only status of this peptide blend, studies and anecdotal reports provide general guidelines:

• Ipamorelin: Commonly dosed at 200–300 mcg per injection, administered 1–3 times daily, preferably on an empty stomach or 30 minutes post-meal to maximize GH release.
• CJC-1295 (No DAC): Typically dosed at 100–200 mcg per injection, 2–3 times daily, or 400 mcg once daily for CJC-1295 with DAC (not included in this blend). A weekly cap of 2,000 mcg is suggested for CJC-1295 DAC.
• Blend Dosing: A 1:1 ratio (e.g., 100 mcg CJC-1295 + 100 mcg Ipamorelin per injection) is often used as a starting point, with total daily doses of 20 μg/kg body weight reported in some studies. Dosing may be split into morning and evening injections for optimal GH pulsatility.
• Cycle Duration: Research cycles typically last 12–16 weeks, with a 3-month minimum suggested for observable effects. Breaks between cycles may prevent receptor desensitization.
• Note: Dosage and administration should be determined by qualified researchers under controlled conditions, with adjustments based on study goals and subject response. Consult relevant literature and ethical guidelines.

Studies indicate that CJC-1295 and Ipamorelin are generally well-tolerated, with mild side effects including:

• Injection site reactions (redness, itching, or pain)
• Headaches, nausea, or lightheadedness
• Water retention or flushing (rare with recommended doses)
• Low-purity peptides may increase side effect risks, so sourcing from reputable vendors with lab-tested products is critical. Long-term effects remain understudied, necessitating cautious research protocols.

• Store lyophilized powder at 2–8°C, protected from light and moisture.
• Reconstitute with sterile bacteriostatic water as per research protocols.
• Avoid repeated freeze-thaw cycles to maintain peptide integrity.

The CJC-1295/Ipamorelin Blend (5mg/5mg) is strictly for research purposes and not for human consumption. It has not been evaluated or approved by the FDA for therapeutic use. Researchers must comply with all applicable regulations and ethical guidelines when handling and studying this product. Always consult a qualified professional before initiating research.